Summary
The industry analysis specialist, has released a new report, “Chronic Obstructive Pulmonary Disease (COPD) – Drug Pipeline Analysis and Market Forecasts to 2016”. The report is an essential source of information and analysis on the global COPD market, a key segment within the pharmaceutical and healthcare industry. This pharma report identifies the key trends shaping and driving the global COPD market. The report also provides insights on the prevalent competitive landscape and the companies expected to significantly alter the market landscape. Most importantly, the report provides valuable insights on the pipeline products within the global COPD sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The scope of the report includes:
- Annualized global COPD market revenues data from 2001 to 2009, forecast for seven years to 2016.
- Geographies covered in this report are the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across phases by mechanism of action, and the emerging trends. The key classes of mechanism of action include phosphodiesterase IV (PDE4) inhibitors, long-acting beta2 agonists (LABA), long-acting muscarinic antagonists (LAMA), long-acting beta2 agonist, inhaled corticosteroid combinations and LABA and LAMA combinations.
- Analysis of the current and future market competition in the global COPD market. The key market players covered are GlaxoSmithKline, Novartis AG, Pfizer Inc, AstraZeneca, Forest Laboratories, Merck & Co, Boehringer Ingelheim and Sepracor Inc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- The key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future COPD market.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of the pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global COPD market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global COPD market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global COPD market landscape? – Identify, understand and capitalize.
Table Of Contents :
1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Chronic Obstructive Pulmonary Disease Market : Market Characterization 6
2.1 Overview 6
2.2 COPD Market Size 6
2.3 COPD Market Forecast and CAGR 7
2.4 Drivers and Barriers for the COPD Market 7
2.4.1 Drivers for the COPD Market 8
2.4.2 Barriers for the COPD Market 8
2.5 Opportunity and Unmet Need 9
2.6 Key Takeaway 10
3 Chronic Obstructive Pulmonary Disease Market : Competitive Assessment 11
3.1 Overview 11
3.2 Strategic Competitor Assessment 11
3.3 Product Profile for the Major Marketed Products in the COPD Market 12
3.3.1 Spiriva® HandiHaler® (Tiotropium bromide inhalation powder) 12
3.3.2 Brovana (Arformoterol) 13
3.3.3 Foradil® Aerolizer™ (formoterol fumarate inhalation powder) 14
3.3.4 Symbicort (budesonide/formoterol fumarate dihydrate) 160/4.5 mcg 15
3.4 Key Takeaway 17
4 Chronic Obstructive Pulmonary Disease Market : Pipeline Assessment 18
4.1 Overview 18
4.2 Strategic Pipeline Assessment 18
4.2.1 Technology Trends Analytic Framework 18
4.3 COPD Therapeutics – Promising Drugs under Clinical Development 20
4.4 Molecule Profile for Promising Drugs under Clinical Development 21
4.4.1 Aclidinium Bromide 21
4.4.2 GW642444 (‘444) 22
4.4.3 Daxas® (roflumilast) 23
4.4.4 NVA237 (Glycopyrronium bromide) 25
4.4.5 PROCHYMAL™ (Human Adult Stem Cells) 26
4.5 COPD Market – Clinical Pipeline by Mechanism of Action 27
4.6 COPD – Pipeline by Clinical Phases of Development 27
4.6.1 COPD Therapeutics – Phase III Clinical Pipeline 28
4.6.2 COPD Therapeutics – Phase II Clinical Pipeline 29
4.6.3 COPD Therapeutics – Phase I Clinical Pipeline 31
4.6.4 COPD Therapeutics – Preclinical Pipeline 32
4.6.5 COPD Therapeutics – Discovery Pipeline 32
4.7 Discontinued Drugs for COPD 33
4.8 Key Takeaway 33
5 Chronic Obstructive Pulmonary Disease Market : Implications for Future Market Competition 34
6 Chronic Obstructive Pulmonary Disease Market : Future Players in the COPD Market 36
6.1 Introduction 36
6.2 GlaxoSmithKline plc. 37
6.2.1 Company Overview 37
6.2.2 Respiratory Disease Portfolio 38
6.3 Almirall S.A 39
6.3.1 Company Overview 39
6.3.2 Respiratory Disease Portfolio 39
6.4 Novartis AG 39
6.4.1 Company Overview 39
6.4.2 Respiratory Disease Portfolio 40
6.5 AstraZeneca 40
6.5.1 Company Overview 40
6.5.2 Respiratory Portfolio 41
6.6 Altana Pharmaceuticals 42
6.6.1 Company Overview 42
6.6.2 Respiratory Disease Portfolio 42
6.7 Pfizer Inc. 42
6.7.1 Company Overview 42
6.7.2 Respiratory Disease Portfolio 43
7 Chronic Obstructive Pulmonary Disease Market : Appendix 44
7.1 Market Definitions 44
7.2 Abbreviations 44
7.3 Research Methodology 45
7.3.1 Coverage 46
7.3.2 Secondary Research 46
7.3.3 Forecasting 46
7.3.4 Primary Research 49
7.3.5 Expert Panels 49
7.4 Contact Us 49
7.5 Disclaimer 49
7.6 Sources 50
1.1 List of Tables
Table 1: Global COPD Therapeutics Market, Revenue ($bn), 2001-2009 7
Table 2: Global COPD Therapeutics Market, Revenue ($bn), 2009–2016 7
Table 3: Major Marketed Products Comparison in COPD Market, 2010 16
Table 4: COPD Therapeutics – Most Promising Drugs Under Clinical Development, 2010 20
Table 5: COPD Therapeutics – Phase III Clinical Pipeline, 2010 28
Table 6: COPD Therapeutics – Phase II Clinical Pipeline, 2010 29
Table 7: COPD Therapeutics – Phase I Clinical Pipeline, 2010 31
Table 8: COPD Therapeutics – Preclinical Pipeline, 2010 32
Table 9: COPD Therapeutics – Discovery Pipeline, 2010 32
Table 10: List of Discontinued Drugs for COPD, 2010 33
Table 11: GlaxoSmithKline plc – Respiratory Disease Pipeline Products, 2010 38
Table 12: Almirall S.A– Respiratory Disease Pipeline Products, 2010 39
Table 13: Novartis AG– Respiratory Disease Pipeline Products, 2010 40
Table 14: AstraZeneca – Respiratory Marketed Products, 2010 41
Table 15: AstraZeneca – Respiratory Pipeline Products, 2010 41
Table 16: Altana Pharmaceuticals – Respiratory Disease Pipeline Products, 2010 42
Table 17: Pfizer Inc – Respiratory Disease Pipeline Products, 2010 43
1.2 List of Figures
Figure 1: Global COPD Therapeutics Market Revenue ($bn) 2001–2016 7
Figure 2: Opportunity and Unmet Need in the COPD Market, 2010 10
Figure 3: Strategic Competitor Assessment of the Major Marketed Products for COPD, 2010 11
Figure 4: Technology Trends Analytic Framework of the COPD Pipeline, 2010 19
Figure 5: Technology Trends Analytic Framework of the COPD Pipeline – Description, 2010 19
Figure 6: COPD Market – Clinical Pipeline by Mechanism of Action, 2010 27
Figure 7: COPD Pipeline by Phase of Clinical Development, 2010 27
Figure 8: Implications for Future Market Competition in the COPD Market, 2010 34
Figure 9: COPD Market – Clinical Pipeline by Company, 2010 36
Figure 10: GlobalData Methodology 45
Figure 11: GlobalData Market Forecasting Model 48
Companies Mentioned
GlaxoSmithKline plc
Almirall S.A
Novartis AG
AstraZeneca
Altana Pharmaceuticals
Pfizer Inc.
To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1141/Chronic-Obstructive-Pulmonary-Disease-COPD-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
Contact Us:
Visionshopsters
Ph : 91-22-40583000
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com
